About Dr. Steven Quay
Dr. Steven Quay is among the top 1% of scientists worldwide, with over 300+ contributions to medicine and over 9,900 citations. Dr. Quay has dedicated his more than 30-year career to the prevention of breast cancer. Over 80 million people have benefited from the medicines he’s invented, and he is currently focused on the prevention of the 2 million yearly breast cancer cases worldwide. In 2009, Dr. Quay founded Seattle-based Atossa Therapeutics to provide a resource for millions of women, men, and their families who have been devastated by breast cancer and other severe breast health conditions. Atossa Therapeutics’ mission is to develop innovative medicines in areas of significant unmet medical needs in oncology. His pioneering efforts in breast cancer research have led to the invention of 7 FDA-approved pharmaceuticals, 87 U.S. patents, and 130 pending U.S. patents.
Pieces of Coverage
Billion Online Readership
Their Challenge
Dr. Quay has gained significant media recognition for his groundbreaking research on the origins of the COVID-19 virus. Yet, his pioneering contributions to women’s breast health remain underappreciated in public discourse. As the Chairman and CEO of Atossa Therapeutics, Dr. Quay is leading a transformative effort to revolutionize breast cancer care by developing innovative therapies designed to meet critical unmet needs. While Dr. Quay’s background as a physician and scientist is not rooted in gynecology or oncology, his dedication to advancing breast health has resulted in groundbreaking treatments that hold immense promise. To maximize the impact of these advancements, greater emphasis on public education and tailored communication can help bridge gaps in understanding and build broader awareness of his visionary work in breast cancer care.
Our Challenge
Dunn Pellier Media (DPM) faced the unique challenge of elevating Dr. Quay’s expertise in women’s breast health following his high-profile success in research on the origins of COVID-19 and other public health initiatives. While his groundbreaking work at Atossa Therapeutics has driven significant advancements in oncology and addressed critical unmet needs, these contributions required translating into messaging that resonated with the media and the public.
Our mission was to position Dr. Quay as a forward-thinking thought leader in the future of women’s breast health, emphasizing his innovative approaches to targeted treatments and individualized preventive measures. Through strategic storytelling and tailored communication, we aimed to bridge the gap between complex scientific achievements and public understanding, ensuring his legacy as a transformative figure in breast cancer care.
Elevate Dr. Quay’s Media Presence to Spotlight His Transformative Impact on Breast Cancer Research and Innovation
DPM set out to do the following:
- Maintain and enhance the current momentum, ensuring that Dr. Quay’s profile remains at the forefront of the breast cancer research landscape
- Expand public awareness surrounding women’s health issues, utilizing Dr. Quay’s work in healthcare as a focal point for education and advocacy
- Continue to educate and inform consumers about women’s health, utilizing targeted media strategies to convey the significance of Dr. Quay’s groundbreaking work and its broader implications.
- Leverage targeted media opportunities, including interviews, feature articles, and thought leadership pieces, to not only showcase Dr. Quay’s expertise but also position him as a thought leader in the healthcare sector
- Elevate Atossa Therapeutics in the healthcare landscape, and strategically shape the narrative around innovative therapies such as (Z)-endoxifen.
Position Dr. Quay and Atossa Therapeutics as Pioneers in Advancing Breast Cancer Care Through Groundbreaking Research and Innovative Therapies
DPM leveraged its expertise to refine and solidify key messaging, ensuring a consistent and compelling narrative as we entered the second year of positioning Dr. Quay and Atossa Therapeutics in the breast cancer space. Our strategy aligned thought leadership with educational initiatives, creating value for audiences while establishing Dr. Quay as a trusted authority in breast cancer research and innovation.
We strategically crafted media pitches that spotlighted Dr. Quay and Atossa’s groundbreaking work with (Z)-endoxifen, highlighting its potential to address unmet needs in oncology. By actively monitoring media opportunities and industry trends, we identified and capitalized on timely topics relevant to breast health, crafting narratives that educated journalists and the public about cutting-edge research and upcoming advancements.
To amplify visibility, we secured podcast opportunities for Dr. Quay to discuss his insights into breast cancer research, innovative therapies, and proactive health practices for women navigating a breast cancer diagnosis. We also ensured Dr. Quay remained accessible for any COVID-19-related inquiries, reinforcing his credibility across multiple domains of public health.
DPM’s proactive, multi-faceted approach ensured that Dr. Quay and Atossa Therapeutics were consistently at the forefront of conversations about the future of breast cancer care, making us the go-to partner for brands seeking to elevate their thought leadership and media presence.
Our Results
Impressive Media Results: Amplifying Dr. Quay’s Voice Across Leading Platforms
Over two years, DPM’s targeted media strategy delivered outstanding results, securing 189 media placements across online, radio, and TV outlets, with a total readership of 7.4 billion. Our efforts ensured widespread visibility for Dr. Quay and Atossa Therapeutics, positioning them as leaders in breast cancer innovation and public health.
Media highlights included prominent features on Real America’s Voice, Telemundo, Fox TV, Fox Business, Forbes, The Daily Signal, Yahoo, The Hill, Medical Daily, NY Post, and The American Conservative and Daily Mail. We also secured impactful meetings at The White House and Congress, reinforcing Dr. Quay’s thought leadership across diverse audiences.
This robust media presence amplified awareness of Dr. Quay’s groundbreaking research. It solidified Atossa Therapeutics’ reputation as an innovator in breast cancer care, driving momentum for the brand while establishing a legacy of trust and expertise.
Media Coverage
